A Phase 3 interventional study of Ibandronate and Denosumab in Postmenopausal Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2013-02-11.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 4th largest by enrollment, is one of 4 that started in 2009, is one of 17 in phase 3, and was the 9th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 833 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 6th largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2009, is one of 14 in phase 3, and was the 10th registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, open-label, parallel group, study being conducted in the United States and in Europe in postmenopausal women. Approximately 800 subjects will be randomized across about 65 sites in a 1:1 ratio to either denosumab 60mg SC Q6M, or ibandronate 150mg PO QM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
GE Lunar Lumbar spine 0.700 \< or = BMD \< and = 0.940 Total hip 0.504 \< or = BMD \< or = 0.756
Hologic Lumbar spine 0.607 \< or = BMD \< or = 0.827 Total hip 0.454 \< or = BMD \< or = 0.698 Both the initial and the repeat DXA scan of the lumbar spine OR the total hip must meet the above eligibility criteria.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibandronate 150mg PO QM (tablet)
Drug: Ibandronate
denosumab 60mg Subcutaneous Q6M (pre-filled syringe)
Drug: Denosumab
Ibandronate 150mg PO QM (tablet)
denosumab 60mg SC Q6M (pre-filled syringe)
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12
Time frame: Baseline to month 12
Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1
Time frame: Baseline to month 1
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12
Time frame: Baseline to Month 12
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Time frame: Baseline to month 12
Participants were randomized from 29 July 2009 through 5 November 2010
| Milestone | Denosumab 60 mg SC Q6M | Ibandronate 150 mg PO QM |
|---|---|---|
| Started | 417 | 416 |
| Completed | 398 | 356 |
| Not completed | 19 | 60 |
| Withdrew: Withdrawal by subject | 9 | 19 |
| Withdrew: Adverse event | 4 | 13 |
| Withdrew: Other | 3 | 9 |
| Withdrew: Lost to follow-up | 1 | 10 |
| Withdrew: Administrative decision | 1 | 2 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Ineligibility determined | 0 | 3 |
| Withdrew: Noncompliance | 0 | 2 |
| Withdrew: Death | 0 | 1 |
| Percentage Change From Baseline | Denosumab 60 mg SC Q6M | Ibandronate 150 mg PO QM |
|---|---|---|
| Total Hip Bone Mineral Density Percent Change From Baseline at Month 12 | 2.2 (2.0 to 2.5) | 0.9 (0.6 to 1.1) |
| Percentage Change From Baseline | Denosumab 60 mg SC Q6M | Ibandronate 150 mg PO QM |
|---|---|---|
| Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1 | -81.1 (-88.0 to -70.9) | -35.0 (-51.9 to -15.3) |
| Percentage Change From Baseline | Denosumab 60 mg SC Q6M | Ibandronate 150 mg PO QM |
|---|---|---|
| Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12 | 1.7 (1.3 to 2.1) | 0.5 (0.1 to 0.9) |
| Percentage Change From Baseline | Denosumab 60 mg SC Q6M | Ibandronate 150 mg PO QM |
|---|---|---|
| Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 | 4.1 (3.7 to 4.5) | 2.1 (1.7 to 2.5) |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibandronate 150 mg PO QM | — | 22/410 (5.4%) | 31/410 (7.6%) |
| Denosumab 60 mg SC Q6M | — | 39/411 (9.5%) | 42/411 (10.2%) |
| Event | Ibandronate 150 mg PO QM | Denosumab 60 mg SC Q6M |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/410 | 3/411 |
| Chest painGeneral disorders | 0/410 | 3/411 |
| Atrial fibrillationCardiac disorders | 0/410 | 2/411 |
| BradycardiaCardiac disorders | 0/410 | 2/411 |
| Sick sinus syndromeCardiac disorders | 0/410 | 2/411 |
| DiverticulitisInfections and infestations | 0/410 | 2/411 |
| Cerebrovascular accidentNervous system disorders | 0/410 | 2/411 |
| Atrioventricular block completeCardiac disorders | 1/410 | 0/411 |
| Cardiac tamponadeCardiac disorders | 1/410 | 0/411 |
| Coronary artery diseaseCardiac disorders | 1/410 | 0/411 |
| Event | Ibandronate 150 mg PO QM | Denosumab 60 mg SC Q6M |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 23/410 | 25/411 |
| Upper respiratory tract infectionInfections and infestations | 9/410 | 21/411 |
| Age Continuous(Years) | Denosumab 60 mg SC Q6M | Ibandronate 150 mg PO QM | Total |
|---|---|---|---|
| Mean | 67.2 ± 8.1 | 66.2 ± 7.8 | 66.7 ± 8 |
| Sex/Gender, Customized(Participants) | Denosumab 60 mg SC Q6M | Ibandronate 150 mg PO QM | Total |
|---|---|---|---|
| Female | 417 | 416 | 833 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Denosumab 60 mg SC Q6M | Ibandronate 150 mg PO QM | Total |
|---|---|---|---|
| White or Caucasian | 348 | 361 | 709 |
| Black or African American | 3 | 4 | 7 |
| Hispanic or Latino | 54 | 42 | 96 |
| Asian | 3 | 4 | 7 |
| American Indian or Alaska Native | 2 | 0 | 2 |
| Other | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 6 | 3 | 9 |
No study locations are listed for this record.
The record gives a start of Jul 2009, a primary completion of Nov 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Osteoporosis, Postmenopausal →